6 Dimensions Capital

Founded 2017


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 36
Average round size
The average size of a deal this fund participated in
Portfolio companies 33
Rounds per year 9.00
Lead investments 11
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 13
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Therapeutics

Considering the real fund results, this VC is 38 percentage points more often commits exit comparing to other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2018. The higher amount of exits for fund were in 2019. This 6 Dimensions Capital works on 16 percentage points less the average amount of lead investments comparing to the other organizations.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the 6 Dimensions Capital, startups are often financed by ARCH Venture Partners, WuXi Healthcare Ventures, Venrock. The meaningful sponsors for the fund in investment in the same round are ARCH Venture Partners, Hillhouse Capital Group, Boyu Capital. In the next rounds fund is usually obtained by Temasek Holdings, Yonghua Capital, Windham Venture Partners.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline GRAIL, CStone Pharmaceuticals, Yiyao The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Pharmaceutical, Medical Device.

We also calculated 3 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of 6 Dimensions Capital:
Typical Co-investors
6 Dimensions Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after 6 Dimensions Capital:

Funds with similar focus

Funds from China, Shanghai
Funds with similar focus located in China, Shanghai:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Engine Biosciences

Artificial Intelligence
Health Care
Machine Learning
$43M26 May 2021 United States, San Francisco

Fog Pharmaceuticals

Health Care
$107M11 Jan 2021 United States, Cambridge


Health Care
$19M08 May 2020 China, Dongcheng District

Kymera Therapeutics

Health Care
$102M12 Mar 2020 United States, Cambridge

Health Care
$170M09 Sep 2019 China, Dongcheng District


$22M14 Jun 2019 United States, Cambridge

NeuSpera Medical

Health Care
Medical Device
$12M20 Feb 2019 United States, San Jose


Health Care
Health Diagnostics
$60M07 Feb 2019 United States, New York

Dewpoint Therapeutics

$60M30 Jan 2019 United States, Cambridge
Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics

– Engine Biosciences announced the successful completion of an oversubscribed $43m Series A funding round.
– Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
– This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore.
– Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio.
– Amy Schulman, Managing Partner at Polaris Partners, has joined the Engine Biosciences Board of Directors.

FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

– FogPharma announced the completion of a $107m Series C financing round.
– The round was led by venBio Partners with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup.
– Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
– FogPharma’s proprietary hyperstabilized α-helical peptides (Helicon™ peptides) are a new class of therapeutics that combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent 6 Dimensions Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: